The Australian sharemarket has defied an “uninspiring picture” painted by the latest earnings season, outperforming both Wall Street and key Asian markets over the past month. The S&P/ASX 200 rallied nearly 4 per cent, surpassing the S&P 500’s 3.6 per cent rise and gains in Japan and South Korea. This notable performance was largely driven by a strong showing from resource companies, which climbed 15 per cent in four weeks, pushing index heavyweight BHP to a new record. An unexpected boost also came from a resurgence in the health care sector, spearheaded by blood plasma giant CSL. CSL, a leading global biotechnology company specialising in the development of therapies for rare and serious diseases, experienced a nearly 50 per cent surge, including a 17 per cent jump on results day – its largest single-day gain in 25 years.
However, UBS equity strategist Richard Schellbach noted that CSL’s recent result “contained no such excitement,” with net profit beating consensus by only 2 per cent, prompting a downgrade to forward earnings. This trend, exemplified by CSL and hearing implant maker Cochlear, suggests major ASX winners were those whose results were merely “not as bad as the market had feared.” With most of the market having reported, an “uninspiring picture” has emerged, leading analysts to cut earnings forecasts for the 2027 financial year by 2 per cent – double the typical pace for this point in the reporting season.
Concerns over rising oil prices and Australia’s interest rate cycle have significantly influenced these downgrades. While health stocks proved the most consistent outperformers on earnings, appearing to have bottomed out due to improved cost performance, the retail sector remains under considerable pressure. JB Hi-Fi, a key industry indicator, saw its shares tank 12.3 per cent after posting record sales growth and profit, yet falling short of market expectations due to a pullback in consumer spending. Endeavour Group also dropped almost 4 per cent, citing similar consumer behaviour, reflecting widespread disappointment in consumer discretionary stocks. Inflation, a common thread in recent earnings reports, continues to challenge companies, with the direction of interest rates remaining the biggest question for the Australian market outlook.
